The Board of GeNeuro
Gordon is a neurologist with outstanding expertise in the treatment of multiple sclerosis. He has played a key role in the approval of several leading MS drugs. As Vice President, Therapeutic Area Head, Neurology with Novartis, Gordon was responsible for the development and registration of Gilenya®, the world’s first oral MS treatment. Prior to Novartis, he led the team responsible for the approval and launch of Tysabri® at Elan; and earlier, he spearheaded the approval of Rebif® with Serono. Gordon previously headed the MS Clinical Research Clinic at McGill and the Clinical Research Center at the Montreal Neurological Institute. He graduated from Queen’s University medical school in Kingston, completed Internal Medicine and Neurology training at McGill University and post-doctoral Neuroimmunology training at UCSF. Gordon has published over 100 peer reviewed articles in the field of neurology.
Neurology, Neurological Clinical Research, Internal Medicine and Neurology